西格列汀对超重糖尿病前期患者能量代谢与棕色脂肪的影响
这项随机双盲安慰剂对照试验在30名超重欧洲裔糖尿病前期男性中评估西格列汀100 mg/天共12周的效果。西格列汀组OGTT葡萄糖偏移降低40%,胰岛素生成指数升高38%,口服处置指数升高44%,血清甘油三酯降低29%,皮下白色脂肪组织FDG摄取增加53%,但棕色脂肪体积和活性主要终点未达到。
要点
- 西格列汀降低OGTT葡萄糖偏移40%,改善胰岛素生成指数和口服处置指数。
- 西格列汀降低血清甘油三酯29%及极大型、大型、中型VLDL颗粒浓度。
- 棕色脂肪体积和活性主要终点未达到,但皮下白色脂肪组织FDG摄取增加53%。
核心结论
- 超重欧洲裔糖尿病前期男性使用西格列汀12周可改善糖耐量和脂质代谢,与皮下白色脂肪组织FDG摄取增加及骨骼肌线粒体基因PGC1β上调相关,而非棕色脂肪。
研究设计与样本
- 随机、双盲、安慰剂对照试验,在荷兰Leiden大学医学中心和Alrijne医院于2015年3月至2016年9月纳入30名超重欧洲裔糖尿病前期男性(年龄45.9±6.2岁;BMI 28.8±2.3 kg/m2),随机分配至西格列汀100 mg/天组(n=15)或安慰剂组(n=15)治疗12周。
主要发现
- 西格列汀组OGTT葡萄糖偏移降低40%(p<0.003),胰岛素生成指数升高38%(p<0.003),口服处置指数升高44%(p<0.003)。
- 西格列汀组血清甘油三酯降低29%,极大型VLDL降低46%、大型VLDL降低35%、中型VLDL降低24%(均p<0.05)。
- 西格列汀组骨骼肌PGC1β mRNA表达升高117%(p<0.05),皮下白色脂肪组织FDG摄取增加53%(p<0.05)。
- 体重、体成分和能量消耗未发生变化;棕色脂肪体积和活性主要终点未达到。
关键数值与推荐
- 西格列汀用法为100 mg/天,疗程12周。
- 主要终点为西格列汀对棕色脂肪体积和活性的影响,未达到。
临床怎么用
- 在超重欧洲裔糖尿病前期男性中,西格列汀12周可改善糖耐量和脂质代谢,效应与皮下白色脂肪组织FDG摄取增加及骨骼肌PGC1β上调相关,而非棕色脂肪。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this study was to evaluate the effect of sitagliptin on glucose tolerance, plasma lipids, energy expenditure and metabolism of brown adipose tissue (BAT), white adipose tissue (WAT) and skeletal muscle in overweight individuals with prediabetes (impaired glucose tolerance and/or impaired fasting glucose). METHODS: We performed a randomised, double-blinded, placebo-controlled trial in 30 overweight, Europid men (age 45.9 ± 6.2 years; BMI 28.8 ± 2.3 kg/m2) with prediabetes in the Leiden University Medical Center and the Alrijne Hospital between March 2015 and September 2016. Participants were initially randomly allocated to receive sitagliptin (100 mg/day) (n = 15) or placebo (n = 15) for 12 weeks, using a randomisation list that was set up by an unblinded pharmacist. All people involved in the study as well as participants were blinded to group assignment. Two participants withdrew from the study prior to completion (both in the sitagliptin group) and were subsequently replaced with two new participants that were allocated to the same treatment. Before and after treatment, fasting venous blood samples and skeletal muscle biopsies were obtained, OGTT was performed and body composition, resting energy expenditure and [18F] fluorodeoxyglucose ([18F]FDG) uptake by metabolic tissues were assessed. The primary study endpoint was the effect of sitagliptin on BAT volume and activity. RESULTS: One participant from the sitagliptin group was excluded from analysis, due to a distribution error, leaving 29 participants for further analysis. Sitagliptin, but not placebo, lowered glucose excursion (-40%; p < 0.003) during OGTT, accompanied by an improved insulinogenic index (+38%; p < 0.003) and oral disposition index (+44%; p < 0.003). In addition, sitagliptin lowered serum concentrations of triacylglycerol (-29%) and very large (-46%), large (-35%) and medium-sized (-24%) VLDL particles (all p < 0.05). Body weight, body composition and energy expenditure did not change. In skeletal muscle, sitagliptin increased mRNA expression of PGC1β (also known as PPARGC1B) (+117%; p < 0.05), a main controller of mitochondrial oxidative energy metabolism. Although the primary endpoint of change in BAT volume and activity was not met, sitagliptin increased [18F] FDG uptake in subcutaneous WAT (sWAT; +53%; p < 0.05). Reported side effects were mild and transient and not necessarily related to the treatment. CONCLUSIONS/INTERPRETATION: Twelve weeks of sitagliptin in overweight, Europid men with prediabetes improves glucose tolerance and lipid metabolism, as related to increased [18F] FDG uptake by sWAT, rather than BAT, and upregulation of the mitochondrial gene PGC1β in skeletal muscle. Studies on the effect of sitagliptin on preventing or delaying the progression of prediabetes into type 2 diabetes are warranted. TRIAL REGISTRATION: ClinicalTrials.gov NCT02294084. FUNDING: This study was funded by Merck Sharp & Dohme Corp, Dutch Heart Foundation, Dutch Diabetes Research Foundation, Ministry of Economic Affairs and the University of Granada.
引用
- Nahon KJ, Doornink F, Straat ME, et al. Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial. Diabetologia. 2018. PMID: 30145664. doi:10.1007/s00125-018-4716-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。